Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine

Exclusion Criteria

• •Mother known or suspected to be seropositive for HIV (testing not required for inclusion)
• •Planned use of any investigational or non-registered product (drug or vaccine) other than the study vaccines during the study
• •Planned administration of immuno-suppressants or other immune-modifying drugs, administration of immunoglobulins and/or any blood products since birth or planned administration during the study.
• •Administration of immunoglobulins and/or any blood products to the mother during pregnancy
• •Neonatal jaundice requiring parenteral treatment (light therapy for physiological jaundice is allowed)
• •At risk of pneumococcal disease or planning to receive Prevenar™ during the study period
• •Administration or planned administration of BCG vaccination during the study period
• •Acute disease at the time of vaccination. For the booster vaccination phase
• •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the booster dose, or planned use during the booster phase.
• •Evidence of previous diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib booster vaccination since the study conclusion visit of the primary vaccination phase.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
• •Administration/ planned administration of a vaccine not foreseen by the study protocol, administration/ planned administration of immunoglobulins and/or any blood products during the period starting 30 days before the administration of the booster dose and ending 30 days after the booster dose.
• •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose."